WPD Pharmaceuticals Inc. (WPDPF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 261.36 Thousand USD | 367.11% |
| 2022 | 55.95 Thousand USD | -96.2% |
| 2021 | 1.47 Million USD | -30.08% |
| 2020 | 2.1 Million USD | -48.26% |
| 2019 | 4.07 Million CAD | 36.04% |
| 2018 | 2.99 Million USD | 799.98% |
| 2017 | 332.65 Thousand USD | 4601.81% |
| 2016 | 7074.98 USD | 442.28% |
| 2015 | 1304.67 USD | 130.4% |
| 2014 | 566.27 USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 203.89 Thousand USD | -20.27% |
| 2024 Q2 | 199.58 Thousand USD | -1.1% |
| 2023 Q4 | 261.36 Thousand USD | 65.95% |
| 2023 Q3 | 157.49 Thousand USD | -24.87% |
| 2023 Q2 | 209.62 Thousand USD | 270.27% |
| 2023 Q1 | 56.61 Thousand USD | -25.36% |
| 2023 FY | 261.36 Thousand USD | 367.11% |
| 2022 Q4 | 75.85 Thousand CAD | 0.0% |
| 2022 FY | 55.95 Thousand USD | -96.2% |
| 2021 Q1 | 2.19 Million USD | 3.98% |
| 2021 FY | 1.47 Million USD | -30.08% |
| 2021 Q3 | 1.69 Million USD | -9.43% |
| 2021 Q2 | 1.86 Million USD | -14.75% |
| 2021 Q4 | 1.47 Million USD | -12.91% |
| 2020 Q3 | 3.14 Million USD | 22.18% |
| 2020 FY | 2.1 Million USD | -48.26% |
| 2020 Q4 | 2.1 Million USD | -33.06% |
| 2020 Q2 | 2.57 Million USD | 0.0% |
| 2019 FY | 4.07 Million CAD | 36.04% |
| 2018 FY | 2.99 Million USD | 799.98% |
| 2017 FY | 332.65 Thousand USD | 4601.81% |
| 2016 FY | 7074.98 USD | 442.28% |
| 2015 FY | 1304.67 USD | 130.4% |
| 2014 FY | 566.27 USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -11214.459% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 86.653% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 97.524% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | 52.662% |
| Rebus Holdings, Inc. | 5000.00 USD | -5127.28% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 99.799% |
| Qrons Inc. | 420.00 USD | -62129.524% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | 66.085% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 99.065% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | 45.612% |
| Skye Bioscience, Inc. | 11.94 Million USD | 97.811% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 99.327% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 96.38% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -242.306% |
| SQZ Biotechnologies Company | 107.18 Million USD | 99.756% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 81.749% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -261.175% |
| Mesoblast Limited | 667.9 Million USD | 99.961% |
| Marizyme, Inc. | 22.01 Million USD | 98.813% |
| Genus plc | 1.02 Billion USD | 99.975% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | 80.759% |
| Pharming Group N.V. | 462.85 Million USD | 99.944% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 92.111% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | 47.627% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | 58.315% |
| ContraFect Corporation | 20.67 Million USD | 98.736% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | 33.046% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | 31.612% |
| IMV Inc. | 31.33 Million USD | 99.166% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 93.696% |
| MultiCell Technologies, Inc. | 126.22 USD | -206970.195% |
| ONE Bio Corp. | 70.08 Million USD | 99.627% |
| Accustem Sciences Inc. | 939.68 Thousand USD | 72.186% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 99.797% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | 39.459% |
| Q BioMed Inc. | 3.51 Million USD | 92.565% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 99.257% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -0.033% |
| Biomind Labs Inc. | 73.81 Thousand USD | -254.061% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.941% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 81.961% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 99.129% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 90.483% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | 61.983% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 89.96% |
| GB Sciences, Inc. | 103.44 Thousand USD | -152.667% |
| Alpha Cognition Inc. | 2.45 Million USD | 89.342% |
| HST Global, Inc. | 1526.00 USD | -17027.392% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | 73.545% |
| Halberd Corporation | 10.13 Thousand USD | -2479.844% |
| Enzolytics Inc. | 361.7 Million USD | 99.928% |
| Agentix Corp. | 261.39 Thousand USD | 0.011% |
| Resverlogix Corp. | 8.11 Million USD | 96.779% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 86.082% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.994% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 99.452% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | 59.14% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -1047.289% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 97.079% |
| AVAX Technologies, Inc. | 7.37 Million USD | 96.457% |
| Zenith Capital Corp. | 7410.00 USD | -3427.179% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.992% |
| Ember Therapeutics, Inc. | 184.00 USD | -141945.652% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | 18.782% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | 71.835% |
| Kadimastem Ltd | 2.3 Million USD | 88.656% |
| Helix BioMedix, Inc. | 3.02 Million USD | 91.36% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 99.504% |
| BioStem Technologies, Inc. | 14.56 Million USD | 98.205% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -357.778% |
| LadRx Corporation | 2.3 Million USD | 88.675% |
| Cell Source, Inc. | 195.17 Thousand USD | -33.915% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 26.088% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | 26.088% |
| NovAccess Global Inc. | 62.24 Thousand USD | -319.875% |
| Affymax, Inc. | 7.44 Million USD | 96.488% |
| Itoco Inc. | 1.4 Million USD | 81.332% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -173.23% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -146.57% |
| Mobile Lads Corp. | 52.00 USD | -502523.077% |
| CytoDyn Inc. | 11.13 Million USD | 97.653% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -82.808% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -1361.767% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | 32.196% |
| SYBLEU INC | 330.46 Thousand USD | 20.911% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | 36.163% |
| International Stem Cell Corporation | 5.39 Million USD | 95.151% |
| Bioxytran, Inc. | 137.63 Thousand USD | -89.892% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 98.258% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 98.424% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -230.841% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | 69.773% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 96.523% |
| Neutra Corp. | 2851.00 USD | -9067.45% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 99.193% |
| PureTech Health plc | 693.97 Million USD | 99.962% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 96.762% |
| IXICO plc | 15.84 Million USD | 98.35% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 96.844% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 99.747% |
| CSL Limited | 38.02 Billion USD | 99.999% |
| Cellectis S.A. | 333.99 Million USD | 99.922% |